AGTC to Participate at Upcoming Virtual Investor Conferences
September 03 2020 - 4:05PM
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a
biotechnology company focused on developing adeno-associated virus
(AAV) based gene therapies for the treatment of rare inherited
diseases, today announced that management will be participating in
the following virtual conferences:
- 2020 Wells Fargo Virtual Healthcare Conference
(September 9-10, 2020) Sue Washer, President & Chief
Executive Officer, will participate in a fireside chat at 9:20 a.m.
ET on Thursday, September 10, 2020.
- H.C. Wainwright 22nd Annual Global Investment Virtual
Conference (September 14-16, 2020)AGTC management will
participate in investor 1x1 meetings on Monday, September 14, 2020
and Tuesday, September 15, 2020.
- Cantor Fitzgerald Virtual Global Healthcare Conference
2020 (September 15-17, 2020)Ms. Washer will participate in
a fireside chat at 2:40 p.m. ET on Wednesday, September 16,
2020.
A live audio webcast of the presentation at the
Wells Fargo and Cantor Fitzgerald conferences can be accessed by
visiting http://ir.agtc.com/events-and-presentations. A replay will
be available on the company's website following the event.
About AGTCAGTC is a
clinical-stage biotechnology company developing genetic therapies
for people with rare and debilitating ophthalmic, otologic and
central nervous system (CNS) diseases. AGTC is a leader in
designing and constructing all critical gene therapy elements and
bringing them together to develop customized therapies that address
real patient needs. The Company’s most advanced clinical programs
leverage its best-in-class technology platform to potentially
improve vision for patients with an inherited retinal disease. AGTC
has active clinical trials in X-linked retinitis pigmentosa and
achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its pre-clinical
programs build on the Company’s industry leading AAV manufacturing
technology and scientific expertise. AGTC is advancing multiple
important pipeline candidates to address substantial unmet clinical
need in optogenetics, otology and CNS disorders.
IR/PR CONTACTS: David
Carey (IR) or Glenn Silver (PR)Lazar FINN PartnersT: (212) 867-1768
or (646) 871-8485david.carey@finnpartners.com or
glenn.silver@finnpartners.com
Corporate Contact:Bill
SullivanChief Financial OfficerApplied Genetic Technologies
CorporationT: (617) 843-5728bsullivan@agtc.com
Stephen PotterChief Business OfficerApplied
Genetic Technologies CorporationT: (617)
413-2754spotter@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Sep 2023 to Sep 2024